Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus

Lupus

Volumn 11, Issue 1, 2002, Pages 52-56

  Mathieu, A ^a   Sanna, G ^a   Mameli, A ^a   Pinna, C ^a   Vacca, A ^a   Cauli, A ^a   Passiu, G ^a   Piga, M ^b  

^a Center for Systemic Rheumatic Diseases   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Brain SPECT; CNS; Cognitive disorders; Iloprost; SLE; Therapy

Indexed keywords

ANTINUCLEAR ANTIBODY; CYSTEINE ETHYL ESTER TC 99M; DNA ANTIBODY; HYDROXYCHLOROQUINE; ILOPROST; INTERLEUKIN 1BETA; PREDNISOLONE;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CASE REPORT; COGNITIVE DEFECT; FEMALE; HUMAN; IMMUNOTHERAPY; NEUROLOGICAL COMPLICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSOPAGNOSIA; RAYNAUD PHENOMENON; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; ILOPROST; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASODILATOR AGENTS;

EID: 0036182527     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu137cr     Document Type: Article

References (26)

1. Cognitive impairment in patients with systemic lupus erythematosus
2. Controversies in lupus: Nervous system involvement
3. Singlc-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus
4. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations
5. Central nervous system involvement in systemic lupus erythematosus: Cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations
6. Cerebrospinal fluid and the choroid plexus during acute immune complex disease
7. Neurofilament antibodies in systemic lupus erythematosus
8. Neuropsychological correlates of serum lymphocytotoxic antibodies in systemic lupus erythematosus
9. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers
10. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus like disease, and the primary antiphospholipid syndrome
11. Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies
12. Nervous system lupus: Pathogenesis and rationale for therapy
13. Raynaud’s syndrome in systemic lupus erythematosus
14. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue Iloprost in man
15. Chemistry of stable prostacyclin analogues: Synthesis of iloprost
16. The anti platelet and cardiovascular actions of a new carbocyclin (ZK36374) equipotent to PGI2 in vitro
17. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1 on human platelet function
18. Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud’s syndrome
19. Aerosolized prostacyclin and Iloprost in severe pulmonary hypertension
20. Protection by Iloprost (stable analogue of prostacyclin) of endothelial damage due to chronic vasospasm in dogs: An electron microscope study
21. Alteration by Iloprost of the vasospastic effects of endothelin-1 in rabbit cerebral vessels
22. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study
23. Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year
24. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis
25. Cytokine production in scleroderma patients: Effects of therapy with either iloprost or nifedipine
26. Iloprost effects on phagocytes in patients suffering from ischaemic diseases: In vivo evidence for down-regulation of alpha M beta 2 integrin